Hopp til hovedinnhold

Natalizumab - Tysabri®

Sist oppdatert: Sist revidert:
Sist revidert av:
  1. Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660‐668. doi:10.1136/jnnp-2019-322326 DOI  
  2. Perumal J, Fox RJ, Balabanov R, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019;19(1):116. Published 2019 Jun 8. doi:10.1186/s12883-019-1337-z DOI  
  3. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858‐1865. doi:10.1212/WNL.0b013e31821e7c8a DOI  
  4. Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmun Rev. 2017;16(6):658‐665. doi:10.1016/j.autrev.2017.04.010 DOI  
  5. Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. Published 2019 Mar 29. doi:10.1177/1756286419837809 DOI  
  6. Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016 Jan 18. pii: jnnp-2015-312221 . pmid:26780938 PubMed  
  7. Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150. Published 2016 Aug 24. doi:10.1186/s12883-016-0674-4 DOI  
  8. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M, Gold R, Hellwig K.. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2020. pmid:32327455 PubMed  
  9. Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, Sparaco M, Rovaris M, D'Arma A, Lugaresi A, Ferrò MT, Grossi P, Di Sapio A, Cocco E, Granella F, Curti E, Lepore V, Trojano M, Patti F; Italian MS Register Study Group. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1297-1303. doi: 10.1136/jnnp-2020-323472. Epub 2020 Oct 14. PMID: 33055141. PubMed  
  10. Arch Neurol. 2008 May;65(5):656-8. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, Gold R. PMID: 18474743 PubMed  
  11. Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016 Mar 27 . pmid:27018481 PubMed  
  12. Cambron M1,2, Hadhoum N3, Duhin E3, Lacour A3, Chouraki A3, Vermersch P3.. JCV serology in time: 3 years of follow-up.. Acta Neurol Scand. 2016 Oct 20. . pmid: 27766611 PubMed  
  13. Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925‐933. doi:10.1016/S1474-4422(17)30282-X DOI  
  14. McGuigan C1, Craner M2, Guadagno J3, Kapoor R4, Mazibrada G5, Molyneux P6, Nicholas R7, Palace J8, Pearson OR9, Rog D10, Young CA11.. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.. J Neurol Neurosurg Psychiatry. 2015. pmid:26492930 PubMed  
  15. Mason L, Yu B, Camilo-Infante C, Richman S, Richert N. Outcomes of asymptomatic progressive multifocal leukoencephalopathy (PML) in Natalizumab-trated mutiple sclerosis (MS) pastients. EAN 2018.
  16. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.. Neurology. 2014 Apr 29;82(17):1491-8 . pmid:24682966 PubMed  
  17. Iaffaldano P1, Lucisano G2, Pozzilli C3, Brescia Morra V4, Ghezzi A5, Millefiorini E6, Patti F7, Lugaresi A8, Zimatore GB9, Marrosu MG10, Amato MP11, Bertolotto A12, Bergamaschi R13, Granella F14, Coniglio G15, Tedeschi G16, Sola P17, Lus G18, Ferrò MT19, Iuliano G20, Corea F21, Protti A22, Cavalla P23, Guareschi A24, Rodegher M25, Paolicelli D1, Tortorella C1, Lepore V26, Prosperini L3, Saccà F4, Baroncini D5, Comi G25, Trojano M; Italian iMed-Web database.. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015; Nov;138(Pt 11):: 3275-86. pmid:26362907 PubMed  
  18. Calabrese M, Pitteri M, Farina G, Bajrami A, Castellaro M, Magliozzi R, Monaco S. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.. J Neurol Neurosurg Psychiatry 2017. pmid:28844068 PubMed  
  19. Mariottini A1,2, Innocenti C3, Forci B1,2, Magnani E1,2, Mechi C2, Barilaro A2, Nistri R1, Fani A3, Saccardi R3, Massacesi L1,2, Repice AM2.. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. Eur J Neurol. 2019 ; Apr;26(4):624-630: 624-630. pmid:30414315 PubMed  
  20. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910. New England Journal of Medicine  
  21. Fagius J, Burman J.. Normal outcome of pregnancy with ongoing treatment with natalizumab.. Acta Neurol Scand. 2014; Jun;129(6):: e27-9. pmid:20370571 PubMed  
  22. Haghikia A1, Langer-Gould A2, Rellensmann G3, Schneider H4, Tenenbaum T4, Elias-Hamp B5, Menck S6, Zimmermann J7, Herbstritt S8, Marziniak M9, Kümpfel T10, Meinl I10, Plavina T11, Gold R1, Hellwig K12.. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014 ; Jul 1;71(7):: 891-5. pmid:24821217 PubMed  
  23. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010; 12: 667-79.
  24. Poster presentasjon ved ECTRIMS 2015: Safety and Efficacy of Extended Dose Natalizumab in Multiple Sclerosis: An Ongoing Multicenter Study. (P3.267)Lana Zhovtis Ryerson et al
  • Hanne Marie Bøe Lunde, spesialist i nevrologi, PhD
  • Øivind Fredvik Torkildsen, spesialist i nevrologi, professor PhD
  • Lars Bø, spesialist i nevrologi, professor dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med

Tidligere fagmedarbeidere

  • Kjell-Morten Myhr, spesialist i nevrologi, professor dr med